logo

OncoTrials - мониторинг клинических исследований

Новые исследования (2025-06-07):

NCT06717113 (Множественная миелома)
NCT06789159 (Диффузная крупноклеточная В-клеточная лимфома)
NCT07007949 (Острый миелоидный лейкоз)
NCT07008820 (Миелодиспластический синдром)


Найдено исследований: 40

NCT06789159 (добавлено: 2025-06-07)

A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

Теги:  #Relapsed|Refractory 

Локации: Honickman Center; Philadelphia; Pennsylvania; United States

NCT06793410 (добавлено: 2025-06-06)

Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation

Vaccination Against Human Papillomavirus (HPV) in Women and Men After Stem Cell Transplantation

Локации: Karolinska University Hospital; Stockholm; Region Stockholm; Sweden,Linköping University Hospital; Linköping; Region Östergötaland; Sweden,Sahlgrenska University Hospital; Gothenburg; Västra Götalands Region; Sweden,Skåne`s University Hospital; Lund; Region Skåne; Sweden,Uppsala University Hospital; Uppsala; Region Uppsala; Sweden

NCT07001540 (добавлено: 2025-06-04)

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation: A Prospective, Multicenter, Single-Arm Clinical Study

Теги:  #Relapsed|Refractory 

Локации: Fudan University Shanghai Cancer Center; Shanghai; Shanghai; China

NCT06846463 (добавлено: 2025-06-03)

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

Phase 2 Trial Utilizing Zanubrutinib in Patients With Diffuse Large B-cell Lymphoma and MYD88 L265P Mutations, CD79B Mutations, NOTCH1 Truncation or Who Are CD5+ by IHC.

Локации: Virginia Commonwealth University; Richmond; Virginia; United States

NCT06898905 (добавлено: 2025-05-22)

Hyperfractionated Dual Equivalent Fractionated Radiation Therapy

Hyperfractionated Dual Equivalent Fractionated (HyDEF) Bridging Radiation Therapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Undergoing T-Cell Redirection Therapy

Теги:  #Relapsed|Refractory 

Локации: Yale University; New Haven; Connecticut; United States

NCT06870487 (добавлено: 2025-05-21)

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers.

An Open-Label Phase 1 Study to Evaluate PF-08046032 as Monotherapy and Part of Combination Therapy in Participants With Advanced Malignancies

Локации: Fred Hutchinson Cancer Center.; Seattle; Washington; United States,NEXT Oncology; San Antonio; Texas; United States,University of Washington Medical Center- Montlake; Seattle; Washington; United States

NCT06977711 (добавлено: 2025-05-20)

Loncastuximab and Roflumilast Added to R-CHOP (Lo-RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

Phase Ib Clinical Trial of Loncastuximab and Roflumilast Added to R-CHOP (Lo-RR-CHOP) for Treatment Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

Локации: University Hospital System; San Antonio; Texas; United States,University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center; San Antonio; Texas; United States

NCT06929624 (добавлено: 2025-05-14)

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

A Phase 3, Open-label, Randomized Study of SHR-A1912 Combined With Rituximab + Gemcitabine + Oxaliplatin (R-GEMOX) Versus R-GEMOX in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Теги:  #Relapsed|Refractory 

Локации: Beijing Cancer Hospital; Beijing; Beijing; China

NCT06829771 (добавлено: 2025-05-14)

Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma

Phase Ib/II Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma

Теги:  #Relapsed|Refractory 

Локации: Affiliated Cancer Hospital of Shandong First Medical University; Jinan; Shandong; China,Beijing Cancer Hospital; Beijing; Beijing; China,Fudan University Shanghai Cancer Center; Shanghai; Shanghai; China,Fujian Cancer Hospital; Fuzhou; Fujian; China,Gansu Provincial Cancer Hospital; Lanzhou; Gansu; China,Harbin Medical University Cancer Hospital; Harbin; Heilongjiang; China,Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University; Zhengzhou; Henan; China,Hubei Cancer Hospital; Wuhan; Hubei; China,Jiangsu Provincial People`s Hospital; Nanjing; Jiangsu; China,Jiangxi Canser Hospital; Nanchang; Jiangxi; China,Liuzhou People`s Hospital; Liuzhou; Guangxi; China,Maanshan People`s Hospital; Ma`anshan; Anhui; China,People`s Hospital of Tianjin (City); Tianjin; Tianjin; China,Puyang Oilfield General Hospital; Puyang; Henan; China,Shanxi Cancer hospital; Taiyuan; Shanxi; China,Sun Yat-sen University Cancer Center; Guangzhou; Guangdong; China,The Affiliated Hospital of Southwest Medical University; Luzho

NCT06768905 (добавлено: 2025-05-02)

Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma

IOMAB-ACT: A Phase Ib/II Multi-institutional Study of 131 I-Apamistamab Followed by CD19-Targeted CAR-T Cell Therapy for Patients With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Теги:  #Relapsed|Refractory 

Локации: University of Texas Southwestern Medical Center; Dallas; Texas; United States

NCT06890884 (добавлено: 2025-05-02)

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)

Локации: Haddasah Medical Center ( Site 0601); Jerusalem; Israel,Sheba Medical Center ( Site 0603); Ramat Gan; Israel

NCT06703892 (добавлено: 2025-04-10)

A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies

An Open-Label, Non-Randomized, Phase I, Prospective, Dose- Finding Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies

Теги:  #Relapsed|Refractory 

Локации: National Taiwan University Hospital; Taipei; Taiwan

NCT06830759 (добавлено: 2025-04-10)

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

EpcoReal: A Multi-country, Prospective Observational Study of Epcoritamab in NHL Comprising Two Patient Cohorts (3L+ (D)LBCL and 3L+ FL)

Локации: Cross Cancer Institute /ID# 271504; Edmonton; Alberta; Canada,Evangelismos Hospital /ID# 272736; Athens; Attiki; Greece,General Hospital of Athens Laiko /ID# 272758; Athens; Attiki; Greece,Health Sciences North /ID# 274738; Sudbury; Ontario; Canada,Krankenhaus Der Barmherzigen Brueder Graz /ID# 273288; Graz; Steiermark; Austria,Papageorgiou General Hospital /ID# 272735; Thessaloniki; Greece,Rabin Medical Center /ID# 271614; Petah Tikva; Israel,University General Hospital of Alexandroupoli /ID# 272737; Alexandroupoli; Evros; Greece

NCT06050694 (добавлено: 2025-04-08)

Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL

Теги:  #Newly diagnosed 

Локации: Princess Margaret Cancer Centre; Toronto; Ontario; Canada

NCT06834373 (добавлено: 2025-04-05)

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Phase 2 Study of Golcadomide With Rituximab as a Bridging Therapy Prior to CAR-T for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)

Теги:  #Relapsed|Refractory 

Локации: Mayo Clinic Health System in Albert Lea; Albert Lea; Minnesota; United States,Mayo Clinic Health System-Eau Claire Clinic; Eau Claire; Wisconsin; United States,Mayo Clinic Health System-Franciscan Healthcare; La Crosse; Wisconsin; United States,Mayo Clinic Health Systems-Mankato; Mankato; Minnesota; United States,Mayo Clinic in Arizona; Scottsdale; Arizona; United States,Mayo Clinic in Florida; Jacksonville; Florida; United States,Mayo Clinic in Rochester; Rochester; Minnesota; United States

NCT06760039 (добавлено: 2025-04-04)

Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL

Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of Low-risk and Medium-risk Diffuse Large B-cell Lymphoma (DLBCL): a Randomized, Controlled, Open-label, Multicenter, Phase Ib/II Clinical Study

Локации: Beijing Tongren Hospital; Beijing; China,Fujian Provincial Cancer Hospital; Fuzhou; Fujian; China,Gansu Provincial Cancer Hospital; Lanzhou; Gansu; China,Ganzhou Cancer Hospital; Ganzhou; Jiangxi; China,Guangxi Zhuang Autonomous Region Cancer Hospital; Guilin; Guangxi; China,Jiangxi Provincial Cancer Hospital; Nanchang; Jiangxi; China,Shenzhen People`s Hospital; Shenzhen; Guangdong; China,The Affiliated Hospital of Guangdong Medical University; Guangzhou; Guangdong; China,The Fifth Affiliated Hospital of Guangzhou Medical University.; Guangzhou; Guangdong; China,The Fifth Affiliated Hospital of Sun Yat-sen University; Zhuhai; Guangdong; China

NCT06902012 (добавлено: 2025-04-01)

Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma

A Prospective, Single - Arm Clinical Study on the Safety and Efficacy of Early Second Infusion of CD19 CAR - T Based on ctDNA Monitoring in the Treatment of Relapsed/Refractory Large B - Cell Lymphoma

Теги:  #Relapsed|Refractory 

Локации: Zhujiang Hospital; Guangzhou; Guangdong; China

NCT06854445 (добавлено: 2025-03-25)

Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma

Phase II Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Теги:  #Relapsed|Refractory 

Локации: Affiliated Cancer Hospital and insititute Guangzhou Medical University; Guangzhou; Guangdong; China,Gansu Provincial Cancer Hospital; Lanzhou; Gansu; China,Guangxi Medical University Cancer Hospital; Nanning; Guangxi; China,Harbin Medical University Cancer Hospital; Harbin; Heilongjiang; China,Henan Cancer Hospital; Zhengzhou; Henan; China,Hubei Cancer Hospital (HBCH); Wuhan; Hubei; China,Hunan Cancer Hospital; Changsha; Hunan; China,Jiangxi Cancer Hospital; Nanchang; Jiangxi; China,Nanjing Drum Tower Hospital; Nanjing; Jiangsu; China,Shandong Cancer Hospital; Jinan; Shandong; China,Shanxi Provincial Cancer Hospital; Taiyuan; Shanxi; China,Sichuan Provincal People`s Hospital; Chengdu; Sichuan; China,The Affiliated Hospital of Southwest Medical University; Luzhou; Sichuan; China,The First Affiliated Hospital of Soochow University; Suzhou; Jiangsu; China,The First Affiliated Hospital of Wannan Medical College; Wuhu; Anhui; China,The First Affiliated Hospital of Xi`an Jiaotong University; Xi`an; Shaanxi; China,T

NCT06536049 (добавлено: 2025-03-22)

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Phase Ib/II Trial of Epcoritamab Plus Ibrutinib in Patients With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Теги:  #Relapsed|Refractory 

Локации: Ohio State University Comprehensive Cancer Center; Columbus; Ohio; United States,University of Minnesota/Masonic Cancer Center; Minneapolis; Minnesota; United States

NCT06784167 (добавлено: 2025-03-21)

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkins Lymphoma Post CAR-T Treatment

Теги:  #Plasma cell leukemia 

Локации: OHSU Knight Cancer Institute; Portland; Oregon; United States

NCT06570447 (добавлено: 2025-03-14)

Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL

An Open-label, Single-arm, Single-center, Phase II Clinical Trial of Glofitamab Combination With Chidamide in Patients With Recurrent and Refractory Diffuse Large B-Cell Lymphoma

Теги:  #Relapsed|Refractory 

Локации: Tianjin Medical University Cancer Insititute & Hospital; Tianjin; Tianjin; China

NCT05990465 (добавлено: 2025-02-20)

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Phase I Study of LV20.19 CAR T-cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Теги:  #Relapsed|Refractory 

Локации: Froedtert & the Medical College of Wisconsin; Milwaukee; Wisconsin; United States

NCT06832267 (добавлено: 2025-02-20)

Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL

A Single-center, Single-arm Phase II Trial of Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for Primary Central Nervous System Diffuse Large B-cell Lymphomas(PCNS DLBCL)

Теги:  #Newly diagnosed 

Локации: Zhejiang Cancer Hospital; Hangzhou; Zhejiang; China

NCT06779435 (добавлено: 2025-02-20)

A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL

A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of Diffuse Large B-cell Lymphoma

Локации: No. 197 Ruijin 2nd Road, Huangpu District, Shanghai; Shanghai; Shanghai; China

NCT06806033 (добавлено: 2025-02-04)

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Теги:  #Relapsed|Refractory 

Локации: A.O. Spedali Civili Di Brescia-P.O. Spedali Civili; Brescia; Lombardia; Italy,Alaska Oncology & Hematology, LLC; Anchorage; Alaska; United States,Arthur J.E. Child Comprehensive Cancer Center; Calgary; Alberta; Canada,Asan Medical Center; Seoul; Korea, Republic of,CancerCare Manitoba (CCMB); Winnipeg; Manitoba; Canada,CancerCare Manitoba; Winnipeg; Manitoba; Canada,Chu de Bordeaux; Pessac; France,Chu de Grenoble; La Tronche; France,CHU DE RENNES - CHU Pontchaillou; Rennes; France,Irccs Istituto Europeo Di Oncologia (IEO); Milano; Lombardia; Italy,IRCCS Istituto Romagnolo per lo studio dei tumori "Dino Amadori"; Meldola; Emilia-Romagna; Italy,Istituto Clinico Humanitas; Rozzano; Lombardia; Italy,Istituto Nazionale Tumori Irccs Fondazione g. Pascale; Napoli; Campania; Italy,Nebraska Cancer Specialists; Omaha; Nebraska; United States,New York Oncology Hematology, P.C.; Albany; New York; United States,Seoul National University Bundang Hospital; Seongnam-si; Korea, Republic of,Valkyrie Clinical Trials; Los Angeles

NCT06765317 (добавлено: 2025-01-29)

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

Optimizing Frontline Therapy for DLBCL in Older Adults: A GLOfitamab-based, Response-adapted, Window-stYle Study (GLORY)

Локации: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities); Basking Ridge; New Jersey; United States,Memorial Sloan Kettering Bergen (Limited Protocol Activities); Montvale; New Jersey; United States,Memorial Sloan Kettering Cancer Center (All Protocol Activities); New York; New York; United States,Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities); Commack; New York; United States,Memorial Sloan Kettering Monmouth (Limited Protocol Activities); Middletown; New Jersey; United States,Memorial Sloan Kettering Nassau (Limited Protocol Activities); Rockville Centre; New York; United States,Memorial Sloan Kettering Westchester (All Protocol Activities); Harrison; New York; United States

NCT06792253 (добавлено: 2025-01-25)

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase Ⅲ Clinical Trial Comparing BEBT-908 Combined With Rituximab (R) to Standard of Care for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Теги:  #Relapsed|Refractory 

Локации: Cancer Hospital Chinese Academy of Medical Sciences; Beijing; Beijing; China

NCT06687772 (добавлено: 2025-01-23)

CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant

Safety and Feasibility Study for CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant (CNS-PHLAT)

Теги:  #Relapsed|Refractory 

Локации: Washington University School of Medicine; Saint Louis; Missouri; United States

NCT06764017 (добавлено: 2025-01-09)

CHiR Therapy for Elderly DLBCL Intolerant to Chemo

A Single-arm, Multicenter, Prospective Clinical Study of CHiR (chidamide, Zanubrutinib, and Lenalidomide) for Newly Diagnosed MYC- and BCL2-positive Diffuse Large B-cell Lymphoma (DLBCL) in Elderly Patients Intolerant to Chemotherapy.

Теги:  #Newly diagnosed 

Локации: The First Affiliated Hospital of Ningbo University; Ningbo; Zhejiang; China

NCT06761677 (добавлено: 2025-01-08)

A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

A Multi-Center, Global, Open-Label, Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma As Well As to Evaluate the Safety and Efficacy of Intravenous Brincidofovir in Patients With Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma Using The Recommended Phase 2 Dose

Теги:  #Relapsed|Refractory 

Локации: Cancer Institute Hospital Of JFCR; Koto-ku; Japan,Mie University Hospital; Tsu; Japan,National Cancer Center Hospital; Chuo-ku; Japan,Okayama University Hospital; Okayama; Japan

NCT06672705 (добавлено: 2025-01-07)

Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders

Phase Ib Study to Assess the Efficacy and Safety of Epcoritamab in Relapsed or Refractory Post-Transplant Lymphoproliferative Disorder

Теги:  #Relapsed|Refractory 

Локации: Ohio State University Comprehensive Cancer Center; Columbus; Ohio; United States

NCT06208735 (добавлено: 2025-01-07)

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

CLIC-02: A Phase I Trial of CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Теги:  #Relapsed|Refractory 

Локации: Alberta Children`s Hospital; Calgary; Alberta; Canada,Arthur J.E. Child Comprehensive Cancer Centre; Calgary; Alberta; Canada,BC Children`s Hospital; Vancouver; British Columbia; Canada,Calgary Cancer Centre; Calgary; Alberta; Canada,Princess Margaret Cancer Centre; Toronto; Ontario; Canada,The Hospital for Sick Children; Toronto; Ontario; Canada,The Ottawa Hospital - General Campus; Ottawa; Ontario; Canada,Vancouver General Hospital; Vancouver; British Columbia; Canada

NCT06758037 (добавлено: 2025-01-04)

Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients with DLBCL Intolerant to Chemotherapy

A Single-arm, Multicenter Phase II Clinical Study of HiR+X Therapy for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) in Elderly Patients Intolerant to Chemotherapy, Guided by Molecular Subtyping and Clinical Characteristics.

Теги:  #Newly diagnosed 

Локации: The First Affiliated Hospital of Ningbo University; Ningbo; Zhejiang; China

NCT06717347 (добавлено: 2024-12-28)

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

Теги:  #Newly diagnosed 

Локации: Aalborg University Hospital ( Site 1302); Aalborg; Nordjylland; Denmark,Affiliated Cancer Hospital of Guangxi Medical University ( Site 3123); Nanning; Guangxi; China,Affiliated Hospital of Nantong University ( Site 3117); Nantong; Jiangsu; China,AOU delle Marche Ospedali Riuniti di Ancona ( Site 2011); Ancona; Italy,ASBL CHU Helora - Hôpital de Mons - Site Kennedy ( Site 1103); Mons; Hainaut; Belgium,Auxilio Mutuo Cancer Center ( Site 1001); San Juan; Puerto Rico,Beijing Cancer Hospital ( Site 3101); Beijing; Beijing; China,Biocenter ( Site 0510); Concepcion.; Biobio; Chile,Blue Ridge Cancer Care ( Site 0132); Roanoke; Virginia; United States,BRCR Global - Mayaguez ( Site 1003); Mayaguez; Puerto Rico,Cancer Blood and Specialty Clinic ( Site 0109); Los Alamitos; California; United States,Cancer Care Specialists of Illinois ( Site 0152); O`Fallon; Illinois; United States,Carmel Hospital ( Site 1903); Haifa; Israel,CELAN,S.A ( Site 0702); Guatemala.; Guatemala,Cen Integral Onco Gastro y Hemato Onco Guatemala S

NCT06736613 (добавлено: 2024-12-19)

A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

Cerebral Spinal Fluid Circulating Tumor DNA (ctDNA) Analysis in Patients With Aggressive B-cell Lymphoma Receiving Front Line Therapy and at High Risk for Central Nervous System Relapse

Теги:  #Relapsed|Refractory 

Локации: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities); Basking Ridge; New Jersey; United States,Memorial Sloan Kettering Bergen (Limited Protocol Activities); Montvale; New Jersey; United States,Memorial Sloan Kettering Cancer Center (All Protocol Activites); New York; New York; United States,Memorial Sloan Kettering Monmouth (Limited Protocol Activities); Middletown; New Jersey; United States,Memorial Sloan Kettering Nassau (Limited Protocol Activities); Rockville Centre; New York; United States,Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities); Commack; New York; United States,Memorial Sloan Kettering Westchester (Limited Protocol Activities); Harrison; New York; United States

NCT06701357 (добавлено: 2024-11-23)

CR-CHOP+X in Previously Untreated DEL

A Prospective, Open-label Phase II Study of Chidamide Plus R-CHOP + X in Previously Untreated Diffuse Large B-cell Lymphoma with Double Expression of MYC and BCL2.

Теги:  #Newly diagnosed 

Локации: No. 197 Ruijin 2nd Road, Huangpu District, Shanghai; Shanghai; Shanghai; China

NCT06693830 (добавлено: 2024-11-19)

ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

Sequencing-guided cHemotherapy Optimization Using Real-Time Evaluation in Newly Diagnosed DLBCL With Circulating Tumor DNA: SHORTEN-ctDNA

Теги:  #Newly diagnosed 

Локации: Columbia University; New York; New York; United States

NCT06667687 (добавлено: 2024-11-03)

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin`s Lymphoma

A Phase 1 First-In-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-291 in Non-Hodgkin`s Lymphoma

Теги:  #Relapsed|Refractory 

Локации: Aichi Cancer Center /ID# 267471; Nagoya-shi; Aichi; Japan,Carolina BioOncology Institute /ID# 265259; Huntersville; North Carolina; United States,Hadassah Medical Center-Hebrew University /ID# 261658; Jerusalem; Yerushalayim; Israel,St Vincent`s Hospital Melbourne /ID# 261664; Fitzroy Melbourne; Victoria; Australia,START Mountain Region /ID# 267592; West Valley City; Utah; United States,Tel Aviv Sourasky Medical Center /ID# 261659; Tel Aviv; Tel-Aviv; Israel,Texas Oncology - Central/South Texas /ID# 270946; Austin; Texas; United States,The Cancer Institute Hospital Of JFCR /ID# 267470; Koto-ku; Tokyo; Japan,Virginia Cancer Specialists - Fairfax /ID# 265082; Fairfax; Virginia; United States,Willamette Valley Cancer Institute and Research Center /ID# 270945; Eugene; Oregon; United States

NCT06533579 (добавлено: 2024-10-17)

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

A Phase 1/2 Safety, Dose-finding, and Pharmacokinetics Study of VNX-101 Gene Therapy in Patients With Relapsed or Refractory CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Теги:  #Relapsed|Refractory 

Локации: City of Hope; Duarte; California; United States,Colorado Blood Cancer Institute; Denver; Colorado; United States,New York Medical College; Valhalla; New York; United States,Oncology Hematology Care; Cincinnati; Ohio; United States,The Ohio State University Wexner Medical Center; Columbus; Ohio; United States,TriStar BMT; Nashville; Tennessee; United States,University of Texas MD Anderson Cancer Center; Houston; Texas; United States

NCT04628494 (добавлено: 2022-01-25)

A Phase 3 Trial of Epcoritamab in R/R DLBCL

A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator`s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Теги:  #Relapsed|Refractory 

Локации: Aalborg Universitetshospital, Aalborg, Denmark,Aarhus University Hospital, Department of Hematology, Clinical Research Unit C116, Aarhus, Denmark,Amerikan Hospital, Istanbul, Turkey,Ankara University Medical Faculty, Ankara, Turkey,Asan Medical Center, Seoul, Korea, Republic of,AZ Delta, Menen, Belgium,Az Groeninge, Kortrijk, Belgium,AZ Nikolaas- Verenigde Ziekenhuizen van Waas en Durme, Sint-Niklaas, Belgium,AZ Sint-Jan, Brugge, Belgium,AZ Turnhout, Campus Sint-Elisabeth, Turnhout, Belgium,Belgyógyászati osztály Markhot Ferenc Kórház, Eger, Hungary,Calvary Mater Newcastle, Waratah, Australia,Centre Antoine Lacassagne, Nice, France,Centre Henri Becquerel, Rouen, France,Centre Hospitalier de la Côte Basque, Bayonne, France,Centre Hospitalier Lyon Sud, Pierre-Benite, France,Centre Leon Berard, Lyon, France,Centrum Medyczne Pratia Poznan, Skorzewo, Poland,Ch Cornouaille, Quimper, France,Chonbuk National University Hospital, Geumam, Korea, Republic of,CHRU de Brest - Hospital Morvan, Brest, France,CHRU Tour